Abstract. Salicylate (aspirin) can reversibly eliminate outer hair cell (OHC) electromotility to induce hearing loss. Prestin is the OHC electromotility motor protein. Here we report that, consistence with increase in distortion product otoacoustic emission, long-term administration of salicylate can increase prestin expression and OHC electromotility. The prestin expression at the mRNA and protein levels was increased by three-to four-fold. In contrast to the acute inhibition, the OHC electromotility associated charge density was also increased by 18 %. This incremental increase was reversible. After cessation of salicylate administration, the prestin expression returned to normal. We also found that long-term administration of salicylate did not alter cyclooxygenase (Cox) II expression but down-regulated NF-kB and increased nuclear transcription factors c-fos and egr-1. The data suggest that prestin expression in vivo is dynamically up-regulated to increase OHC electromotility in long-term administration of salicylate via the Cox-II-independent pathways.
Introduction
Normal mammalian hearing relies upon active cochlear mechanics to amplify acoustic stimulation [1] . In the mammalian cochlea, outer hair cells (OHCs) have electromotility [2] . The OHC can rapidly change cell length to boost the basilar membrane vibration thereby increasing hearing sensitivity and frequency selectivity [1, 3, 4] . Prestin has been identified as the motor protein responsible for OHC electromotility [5] .
Prestin locates at the OHC lateral wall [6, 7] and combines with Cl -ions as an external voltage sensor [8] to drive cell movement by membrane potential. Molecular genetic studies demonstrate that OHC electromotility is a major contributor to active cochlear mechanics in mammals. Knockout of prestin results in reduction of distortion product otoacoustic emissions (DPOAEs) and hearing loss [9, 10] . Although prestin as a motor protein responsible for OHC electromotility has been well documented, little is known about its expression and regulation in vivo due to a lack of proper animal models. Aspirin (salicylate) is a well-known ototoxic agent [11] .
Salicylate can competitively bind motor protein prestin with its external voltage sensor of Cl -ions, reversibly inhibiting OHC electromotility [8, 12] . In the clinic, acute consumption of aspirin can cause a reversible decrease in acoustic emission and hearing loss [11] . However, in contrast to the acute inhibition, daily administration of salicylate can cause tinnitus [11, 13 -16] , which is a virtual conscious sound perception arising from the neural over-activity in the auditory system. We have also reported that, in contrast to the acute inhibition, long-term administration of salicylate paradoxically increases otoacoustic emissions [17] , indicating that long-term administration of salicylate increases active cochlear mechanics. In this study, the expression and regulation of prestin in long-term administration of salicylate have been studied. Long-term administration of salicylate up-regulated prestin expression and increased OHC electromotility to enhance active cochlear mechanics. This incremental increase is reversible. The prestin expression returned to normal after cessation of salicylate administration. The data indicate that the prestin expression in vivo can be dynamically regulated to meet functional demands. Preliminary data of this work have been reported in an abstract form [18] .
Methods and materials
Salicylate administration and animal preparation. Sodium salicylate was purchased from Sigma (St. Louis, MO), and was freshly dissolved in saline. According to Jastreboffs tinnitus model [13, 14, 19] , the adult guinea pigs (200 -250 g) or mice (25 -30 g, 6 -8 weeks) were intraperitoneally injected with sodium salicylate (245 mg/kg, i.e., 200 mg/kg salicylate) twice per day for 2 weeks. At the same time, control animals were injected with the equal amounts of saline. The day of the first injection was defined as day 0. All experimental procedures were conducted in accordance with the policies of University of Kentuckys Animal Care and Use Committee.
In vivo acoustic emission recording. Guinea pigs were anaesthetized with sodium pentobarbital (30 mg/kg) and DPOAE was measured using a CELESTA Cochlear Emission Analyzer (Madsen, Denmark) as described previously [17] . A cubic distortion product of 2f 1 -f 2 was recorded from frequency 0.5 -8 kHz with f 2 /f 1 = 1.22 at intensity of L 1 /L 2 = 55/50 dB SPL. DPOAE was measured at day 0, and after 1 and 2 weeks of salicylate or saline injections. For measurement of the acute effect, DPOAE was recorded before and 1, 2, 4, and 8 h after injection (see Fig. 1A ).
Cochlea and OHC isolation. After 2 weeks of injections, the animals were decapitated after intraperitoneal injection of a lethal dose of sodium pentobarbital (200 mg/kg). The temporal bones were removed. The cochlea was dissected into an extracellular solution (142 mM NaCl, 5.37 mM KCl, 1.47 mM MgCl 2 , 2 mM CaCl 2 , 10 mM HEPES, 300 mOsm and pH 7.2) by a standard technique [7, 20] . The cochlea was opened and the sensory epithelium (organ of Corti) was isolated using a sharpened needle. The isolated sensory epithelium was incubated with trypsin (1 mg/ml) in the standard extracellular solution for 5 -15 min to dissociate OHCs. The dissociated OHCs were used in immunofluorescence staining or transferred to the recording dish for patch recording. All isolation and recording were performed at room temperature (23 8C). Patch-clamp recording and nonlinear capacitance measurement. For patch recording, eight salicylatetreated, seven saline-injected and five normal guinea pigs were used. The standard whole-cell patch clamp recording was performed using an Axopatch 200B (Axon, CA) with jClamp (SciSoft, CT) [4, 20] . A patch pipette was filled with an intracellular solution (140 mM CsCl, 5 mM EGTA, 2 mM MgCl 2 , and 10 mM HEPES, pH 7.2, 300 mOsm) and had initial resistance of 2.5 -3.5 MW in bath solution. OHC electromotility-associated nonlinear capacitance (NLC) was measured by a two-sinusoidal method and fitted to the first derivative of a two-state Boltzmann function [20, 21] :
where NLC is the nonlinear capacitance component associated with OHC electromotility, C lin is the linear cell membrane capacitance, Q max is the maximum charge transferred, V m is the membrane potential corrected for electrode access resistance, V pk is the potential that has an equal charge distribution; z is the number of elementary charge (e), k is Boltzmanns constant and T is the absolute temperature.
The whole cochlear RNA extraction and real-time RT-PCR measurement. We adopted a variation of the protocol previously reported by Dr. Zheng [22] . The cochlea was freshly isolated and the whole cochlea was homogenized with one cochlea per tube. Prestin Western blotting. The whole cochlea was crushed in a modified RIPA cell lysis buffer (10 mM Tris, 100 mM NaCl, 2 mM EDTA, 0.1 % SDS, 1 % Triton X-100, protease inhibitor cocktail and 1 mM PMSF), frozen and sonicated. Lysates were centrifuged at 3000 g, 4 8C for 15 min. The supernatant was collected and denatured with Laemmli loading buffer at 50 8C for 20 min. Then, whole cochlear lysates were loaded at one cochlea per well onto the 4 -12 % gradient Pre-Cast Tris-glycine sodium dodecyl sulfate-acrylamide gel (Cat. no. EC6038Box, Invitrogen). After electrophoresis, the proteins in the gel were electrotransferred onto an immunoblot PVDF membrane. The membrane was blocked with 5 % non-fat dry milk and 5 % fetal bovine serum, and then Table 1 . PCR primers.
incubated with anti-prestin antibodies (1 : 2500, a kind gift of Dr. Zheng at the Northwestern University). After being washed with Tris-buffered saline with 0.1 % Tween 20, the membrane was incubated with the secondary antibody (horseradish peroxidase-conjugated goat anti-rabbit IgG) in PBS with 5 % non-fat dry milk and 5 % fetal bovine serum. Finally, after being thoroughly washed with Tris-buffered saline with 0.1 % Tween 20, membranes for measuring prestin expression were incubated with SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford, IL) for 2 min and exposed to X-ray film to detect the ECL signal.
To control for internal errors, the salicylate, saline, and/or normal samples were run together in the same gel. GAPDH was used as an internal control. The blots were scanned and measured by UN-SCAN-IT blotting analysis software (Silk Scientific Corp., UT), and then normalized to GAPDH.
Immunofluorescence staining and confocal microscopy. Immunofluorescent staining for prestin was performed as previously reported [7] . Three salicylate-treated, three saline-injected and five normal guinea pigs were used for immunofluorescence staining. The dissociated cochlear cells were fixed with 4 % paraformaldehyde in 0.1 M PBS (pH 7.4) for 30 min. After being washed with PBS, the cells were incubated in a blocking solution (10 % goat serum and 1 % BSA in the PBS) with 0.1 % Triton X-100 for 20 min at room temperature, then incubated with primary antibody anti prestin-C terminus (1 : 1000, a kind gift of Dr. Jing Zheng at Northwestern University) or antibodies for c-fos, egr-1 and PPARg (1 : 100, Santa Cruz Biotech Inc, Santa Cruz, CA) at 4 8C overnight. After completely washing out the primary antibodies with PBS, reaction to a 1:600 dilution of secondary Alexa Fluor 488 or 568 conjugated antibodies (Molecular Probes) in the blocking solution was followed at room temperature for 1 h to visualize binding of the primary antibodies. The staining was observed under a confocal laser-scanning microscope (Leica TCS SP2). To limit errors, immunofluorescence staining of cochlear cells derived from different groups were performed in parallel at the same time and observed under the same confocal settings. All images were saved in the TIFF format. The immunofluorescent labeling for prestin at the OHC lateral wall was quantitatively analyzed by NIH image software (Bethesda, MD) as described previously [7] . The intensity of labeling at the OHC lateral wall above the nuclear level was measured using the "Plot Profile" function. The intensity profile was then defined by Gaussian fitting and averaged for both sides.
Data presentation and statistical analysis. Data were plotted by SigmaPlot software (SPSS Inc., Chicago). The statistical analyses were performed using commercial software, SPSS v10.0 (SPSS Inc, Chicago, IL). Error bars represent SE.
Results
Dual effects of salicylate on acoustic emissions. Acute administration of salicylate can eliminate otoacoustic emissions. Figure 1A shows that injection of salicylate quickly reduced DPOAEs. The inhibition occurred at 1 h after injection of salicylate and lasted for 1 -2 h. This acute inhibition is reversible. After 6 -8 h the acoustic emission was almost completely recovered. However, following daily administration of salicylate, otacoustic emissions increased (Fig. 1B) . The DPOAE significantly increased after administration of salicylate for 1 and 2 weeks, consistent with our previous report [17] .
Prestin up-regulation on long-term administration of salicylate. Prestin expression was up-regulated during long-term administration of salicylate (Figs. 2, 3) . Following daily administration of salicylate, the prestin mRNA was progressively increased (Fig. 2) . The significant increase was detected after injection of salicylate for 3 days (Fig. 2C) . After injection for 2 weeks, the amount of prestin mRNA had increased by 3.31-fold in guinea pigs (Fig. 2B, C ) and 2.5-fold in mice (Fig. 2B ). In the control groups with saline injection, the prestin mRNA level showed no significant changes (Fig. 2B) . The increase was reversible (Fig. 2C) . After cessation of salicylate administration for 4 weeks, the prestin mRNA level returned to normal (Fig. 2C) ; the normalized amount of prestin mRNA was 99.8 AE 21.2 % (n = 5). Prestin proteins also increased during long-term administration of salicylate (Fig. 3) . In the Western blot, two bands corresponding to prestin monomer (~86 kDa) and dimer (~172 kDa) are visible (Fig. 3A) . After administration of salicylate, the intensities of both bands were significantly increased. The increments in the blot intensity of the monomer and dimer were 267.1 AE 66.0 and 422.1 AE 106.5 %, respectively, and in total increased by 3.33-fold after administration of salicylate for 2 weeks (Fig. 3B ) (p = 0.003, ANOVA). The increase was also reversible. At 4 weeks after cessation of salicylate administration, the prestin protein level had decreased to 118.1 AE 15.3 % (n = 5), similar to the prestin protein level measured in the saline and normal control groups (Fig. 3B) . We also used immunofluorescent labeling to examine the functional distribution of prestin proteins at the 2410 N. Yu et al. Salicylate increases prestin expression OHC lateral wall (Fig. 3C, D) . After injection of salicylate for 2 weeks, labeling for prestin at the OHC basolateral wall was increased (Fig. 3D) . The intensities of prestin labeling at the OHC lateral wall in the salicylate, saline and normal animal groups were 118.3 AE 4.5 (n = 48), 45.3 AE 4.5 (n = 40), and 42.3 AE 2.1 (n = 46) (arbitrary unit of fluorescent intensity), respectively (Fig. 3D ). There was a 2.8-fold increase in the salicylate-treated group. However, there was no significant difference between the saline and normal animal groups (p = 0.72, ANOVA).
Long-term administration of salicylate increases OHC electromotility. In contrast to acute inhibition, long-term administration of salicylate increased OHC electromotility (Fig. 4) . After injection of salicylate for 2 weeks, the OHC electromotility-associated NLC was increased (Fig. 4B) . The averaged values of NLC recorded from the normal, salicylate-treated and saline-injected groups were 22.16 AE 1.09 pF (n = 21), 25.3 AE 0.5 pF (n = 39) and 22.3 AE 0.9 pF (n = 25), respectively (Fig. 4C) . The NLC was increased by 14 % in the salicylate group. The increase was significant (p=0.004, ANOVA). The maximum of charge movement (Q max ) was also significantly increased by 16 % in the salicylate group (Fig. 4F , p = 0.0004, ANOVA). The ratio of NLC/C lin , which represents the density of prestin expression on the OHC surface, was 1.02AE0.02 (n = 39) and 0.87 AE 0.03 (n = 25) in the salicylatetreated group and saline control group, respectively (Fig. 4D , p = 0.0003, ANOVA). After C lin was corrected by subtraction of 4.38 pF for the OHC cuticular plate since it has no NCL and prestin distribution [7, 23] , the ratio of NLC/C lin in the salicylate group increased by 17.9 %. However, there was no difference between the saline-injected group and normal animals. The ratio of NLC/C lin in the normal control group was 0.88 AE 0.03 (n = 21). The recorded cell lengths in the normal, salicylate, and saline groups were 67.1 AE 2.1 mm, 68.9 AE 0.7 mm and 70.4 AE 1.1 mm, respectively, and had no significant difference (p = 0.26, ANOVA). On the other hand, after longterm administration of salicylate, the valence (z) of motor charge movement was 0.77 AE 0.01 and showed a slight increase as compared with 0.72 AE 0.02 in the normal group and 0.72 AE 0.03 in the saline control group (Fig. 4G) . However, the increase was not significant (p = 0.078, ANOVA). Long-term administration of salicylate also did not alter the voltage dependence of OHC electromotility. The voltage of peak capacitance (V pk ) in the salicylate group and saline group was -37.2 AE 1.5 mV and -37.0 AE 1.9 mV, respectively (Fig. 4H) . After long-term administration of salicylate, an acute inhibitory effect of salicylate on OHC electromotility still remained (Fig. 5) . Perfusion of salicylate could also reversibly eliminate the NLC (Fig. 5A, B) . Moreover, the elimination became fast (Fig. 5C, D) . The average time constant of elimination for perfusion of 10 mM salicylate was 15.21 AE 1.71 ms (n = 10) and 25.89 AE 1.63 ms (n = 7) in the salicylate-treated group and control group, respectively (Fig. 5D ). The time constant in the salicylate-treated group was almost 2-fold faster than that in the saline control group. NLC was reduced by 12.86 AE 1.17 and 10.93 AE 0.91 pF in the salicylate-treated group and saline control group, respectively. There was no significant difference between them (p = 0.24, ANOVA).
Effect of salicylate on OHC distortion product generation. Long-term administration of salicylate also increased the distortion product generation in the OHCs (Fig. 6A, B) . The cubic distortion component of 2f 1 -f 2 , which is usually measured in the DPOAE measurement in the clinic, had a 36.7 % increment (Fig. 6B) . Acute perfusion of salicylate during patchclamp recording also inhibited the generation of distortion products (Fig. 6C) . The distortion products were reduced by 30 -90 %, and this inhibition was Research Article 2411 reversible. Washout of salicylate quickly restored the generation of distortion products (Fig. 6D) . These data are consistent with the in vivo recording that DPOAE was rapidly reduced after an injection of salicylate but paradoxically increased in long-term administration (Fig. 1A, [17] ).
Effect of salicylate on other cochlear genes for tinnitus generation. Besides prestin expression, we also examined the effect of long-term administration of salicylate on the expression of myosin VIIa. Myosin VIIa has been found to play an important role in the hair bundle-based active cochlear amplifier [24] . Longterm administration of salicylate did not increase the myosin VIIa expression (Fig. 7A) . In contrast to upregulation of prestin expression, the expression of myosin VIIa was reduced by 31.7 %. However, the reduction was not significant (p = 0.08, t-test). A previous report also suggested that increased activation of cochlear N-methyl-D-aspartate (NMDA) receptors was related to salicylate-induced tinnitus [25] . However, long-term administration of salicylate did not significantly increase the expression of NMDA receptors at the transcriptional level ( Fig. 7B ; p = 0.89, t-test). The mRNA level of NMDA receptors in the cochlea after 2 weeks of salicylate injections was 114.8 AE 18.2 % (n = 6).
Alteration of signaling transduction pathways in longterm administration of salicylate. The best-known effect of salicylate is the inhibition of the activity of cyclooxygenases (Cox) [11, 26] . Two Cox isoforms have been identified. Cox-I is constitutively expressed in almost all tissues and its activity depends solely on the availability of its substrate. In contrast, Cox-II is subject to rapid regulation at the transcriptional level.
To determine whether changes in OHC electromotility and prestin expression on long-term administration of salicylate were linked to cyclooxygenase inhibition, we examined the effect of long-term administration of (Fig. 7C) . The expression of Cox-II in the salicylate group was the same as that in the saline control group. Salicylate can also inhibit the activation of nuclear factor (NF)-kB via a Cox-independent pathway for anti-inflammation and a glucose-lowing effect [26 -28] . After 2 weeks of salicylate injections, the expression of NF-kB decreased significantly. The amount of mRNA was reduced by 57 % (Fig. 7D) . NF-kB is regulated primarily by interaction with inhibitor IkB [26, 27] . The expression of IkB was increased by 6-fold after administration of salicylate for 2 weeks (Fig. 8B) . We also examined the effect of long-term administration of salicylate on the expression of transcription factors. We found that transcription factors c-fos, egr-1, and PPARg were significantly increased by 4.17-, 4.71-, and 9.85-fold, respectively, after 2 weeks of salicylate injections (Fig. 8B) . Immunofluorescence staining shows that c-fos and egr-1 were expressed in the OHC nuclei, while PPARg had no expression in OHCs (Fig. 8A) , indicating that transcription factors c-fos and egr-1 may be involved in the up-regulation of prestin expression.
Discussion
In this study, we found that long-term administration of salicylate increased prestin expression (Figs. 2, 3 ) and OHC electromotility (Figs. 4 -6) , consistent with the previous report that long-term administration of salicylate can enhance active cochlear mechanics [17] . So far, two mechanisms of active cochlear mechanics have been proposed: One is the prestin-based OHC electromotility. Knockout of prestin can result in the reduction of DPOAEs and hearing loss [9, 10] . The second is stereocilium-based hair bundle movement, in which myosin VIIa plays an important role [24] . In this study, we found that long-term administration of salicylate did not increase myosin VIIa expression (Fig. 8A ). This suggests that the long-term administration of salicylate-induced enhancement in acoustic Research Article emission is likely to result from the increase in OHC electromotility rather than enhancement in hair bundle movement. This inference is also supported by recent studies that indicate that prestin determines mammalian active cochlear mechanics [29 -32] .
Prestin expression and functional increase in longterm administration of salicylate. After 2 weeks of salicylate injections, prestin expression and OHC electromotility-associated NLC increased (Figs. 2 -4 ). The ratio of NLC/C lin was increased by 18 % (Fig. 4) . OHC electromotility originates from the OHC lateral wall [33, 34] . It has been reported that a high density (5000 -7000/mm 2 ) of particles, which have been considered as prestin motor proteins, embeds in the plasma membrane at the OHC lateral wall. These particles appeared rounded, having 10 -12-nm diameter [35 -37] . Thus, under the normal condition, the area occupied by these particles is 3.14 6 2 (nm) 7000 = 0.79 mm 2 /mm 2 , i.e., prestin proteins occupy 79 % of the surface area at the OHC lateral wall. In other words, there is only about 20 % of free-space remaining on the OHC lateral wall surface to allow packing of increased prestin proteins. Our recorded increase in the charge density (18 %, Fig. 4 ) is compatible with this maximum allowable increase. Therefore, prestin had an almost maximal increase on the OHC lateral wall surface after 2 weeks of salicylate injections. However, prestin at the protein level was increased by more than 3-fold after 2 weeks of salicylate injections (Fig. 3) . The immunofluorescent labeling also showed that the intensity of prestin labeling at the OHC lateral wall was increased by 2.8-fold after long-term administration of salicylate (Fig. 3D) . Several lines of evidence can explain this discrepancy. First, prestin proteins may form oligomers to function at the OHC lateral wall. It has been reported that prestin can form dimers, trimers, and even tetramers in the plasma membrane [38, 39] . In this study, we found that prestin dimer protein expression increased significantly (4.2-fold) as compared with the monomer (2.7-fold) after long-term administration of salicylate (Fig. 3) . Second, the increased prestin protein may be transported to the OHC basolateral wall, but may not all pack into the plasma membrane to achieve function. The OHC lateral wall is composed of the plasma membrane, cortical lattice, and subsurface cisternae (SSC) [1] . The SSC is a multiple-layer membrane structure. In the guinea pig, as many as 12 layers have been Research Article observed [40] . We have proposed that the SSC may serve as a reservoir underlying the plasma membrane in the OHC lateral wall for prestin recycling [7] . The remainder of prestin may accumulate in the SSC beneath the plasma membrane or even in the cytoplasm. Indeed, besides strong labeling for prestin observed at the OHC basolateral wall, prestin labeling could be detected in the cytoplasm (where normally no prestin labeling is visible) of some OHCs after long-term administration of salicylate (data not shown). After long-term injections of salicylate, the acute administration of salicylate could still eliminate OHC electromotility and distortion product generation (Figs. 5, 6 ). Moreover, the inhibition occurred quickly (Fig. 5C ). The time constant was decreased by 70 % (Fig. 5D ). It has been reported that salicylate competitively binds the anionic binding site in the prestin with Cl -ions at the cytoplasmic site to inhibit OHC electromotility [8, 12] . Prestin is a member of SLC26, which is a sulfate-anion transport family, and may also possess the transporter function to exchange Cl -and other anions [41] . Long-term administration of salicylate increased prestin expression (Figs. 2, 3 ) and may increase anionic cross-membrane transfer as well to speed the salicylate effect.
Up-regulation and functional dependence of prestin expression. It has been reported that besides inhibition of Cox, large doses of salicylate can increase IkB to inhibit NF-kB activity to activate non-Cox pathways for anti-inflammatory and glucose-lowing effects [26 -28] . In this study, we found that long-term administration of salicylate did not alter the Cox-II expression (Fig. 7C ) but increased IkB expression to activate the NF-kB signaling pathway and up-regulated c-fos and egr-1, which are expressed in the OHC nuclei (Figs. 7D, 8) . These results suggest that the NFkB signaling pathway may also account for this salicylate-induced prestin up-regulation. The prestin expression was up-regulated to increase OHC electromotility (Figs. 2, 4) . This incremental increase could compensate for the inhibitory effect of salicylate on active cochlear mechanics during salicylate administration (Figs. 1A; 5; 6C, D). In this study, we further found that this prestin up-regulation was reversible (Figs. 2, 3 ). After cessation of salicylate injections, the prestin expression returned to its original level (Figs. 2C, 3B ). This demonstrates that the prestin expression can be regulated according to hearing function even though OHCs cannot be refreshed or regenerated within the life span.
Possible mechanisms of tinnitus generation in longterm administration of salicylate. Long-term administration of salicylate has been shown to cause tinnitus generation [13, 14, 25] . Chronic use of low therapeutic doses of salicylate (aspirin) can induce only tinnitus, and does not inevitably lead to hearing loss [11, 16] . It has been hypothesized that salicylate can alter the neural activity in the auditory centers for tinnitus generation [16] . However, many lines of evidence indicate that the cochlear source plays a central role in the salicylate-induced tinnitus generation. Long-term administration of salicylate has been shown to raise the cochleoneural activity [19, 42] . The increase is reversible, and corresponds well with tinnitus occurrence. It has also been hypothesized that an imbalance between inner hair cell and OHC activities in the cochlea can trigger tinnitus generation [43] . We have reported that long-term administration of salicylate increases DPOAEs [17] . In this study, we further demonstrated that long-term administration of salicylate up-regulated prestin expression (Figs. 2, 3 ) and increased OHC electromotility-associated NLC (Fig. 4) , in concordance with enhancement in active cochlear mechanics (Fig. 1B, [17] ). These data provide a new molecular and genetic clue for further understanding the mechanisms underlying tinnitus generation. 
